Rapport climbs as lead asset succeeds in mid-stage trial for bipolar mania
ModernLife
Rapport Therapeutics (RAPP) surged more than 50% in premarket trading on Tuesday after a mid-stage trial for its lead candidate, RAP-219, succeeded in adults with acute bipolar mania, a psychiatric condition with no new medication in decades.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.